FINWIRES · TerminalLIVE
FINWIRES

GE HealthCare's Continued Underperformance in Patient Care Solutions Business 'Disappointing,' Oppenheimer Says

By

GE HealthCare Technologies' (GEHC) continued underperformance in the Patient Care Solutions business is "disappointing," with the segment experiencing fulfillment challenges in Q2, Oppenheimer said in a Thursday note.

The company is exploring a strategic review for PCS, which includes either continued ownership, sale, or other value enhancing transactions, Oppenheimer said, adding that the timeline of the review remains unclear, with GE HealthCare looking to stabilize the business first.

Additionally, the company reiterated organic revenue growth at 3% to 4%, as well as adjusted earnings per share $4.80 to $5.00, compared with Oppenheimer estimate of $4.90, according to the note.

Oppenheimer said it remains constructive long-term given the company's ecosystem and multiple growth levers, although China, tariffs, and other macro pressures remain as overhangs.

Oppenheimer maintained its outperform rating with a price target of $85 on GE HealthCare.

Price: $69.04, Change: $-2.86, Percent Change: -3.98%

Related Articles

Wire

Houlihan Lokey Fiscal Q1 Adjusted Earnings, Revenue Fall; Shares Drop After Hours

Houlihan Lokey (HLI) reported fiscal Q1 adjusted earnings late Wednesday of $1.35 per diluted share, down from $2.14 a year earlier.Analysts polled by FactSet expected $1.64.Revenue in the three months ended June 30 fell to $511 million from $605 million a year earlier.Analysts expected $602.4 million.Houlihan Lokey shares fell 6.6% in after-hours trading.

$HLI
Wire

Four Corners Property Trust Q2 AFFO, Revenue Rise

Four Corners Property Trust (FCPT) reported Q2 adjusted funds from operations late Wednesday of $0.45 per diluted share, up from $0.44 a year earlier.Analysts polled by FactSet expected $0.45.Revenue in the quarter ended June 30 rose to $78.4 million from $72.8 million a year earlier.Four analysts expected $79 million.The company's shares rose 2% in after-hours trading.

$FCPT
Wire

Corcept Therapeutics Q2 Earnings, Revenue Rise; Shares Jump After Hours

Corcept Therapeutics (CORT) reported Q2 earnings late Wednesday of $0.36 per diluted share, up from $0.29 a year earlier.Analysts polled by FactSet expected $0.02.Revenue for the three months ended June 30 rose to $256.1 million from $194.4 million a year earlier.Analysts expected $221.1 million.The company boosted full-year revenue guidance to $1.1 billion to $1.2 billion from the prior forecast of $950 million to $1.05 billion.Analysts project $999.5 million.Corcept shares jumped 18% in after-hours trading.

$CORT